FrancophonIA/ELRC3.0 huggingface dataset:
English: The Agency concluded that the benefits of Diotop outweigh its risks, and the marketing authorisation granted in the United Kingdom can be recognised in other Member States of the EU where the company has applied for a marketing authorisation.
Estonian: EMA järeldas, et Diotopi kasulikkus on suurem kui sellega kaasnevad riskid ja et Ühendkuningriigis antud müügiluba saab tunnustada teistes Euroopa Liidu liikmesriikides, kus ettevõte on taotlenud müügiluba.
English: However, the Member States were not able to reach an agreement and the UK medicines regulatory agency referred the matter to EMA for arbitration on 28 September 2018.
Estonian: Liikmesriigid ei jõudnud üksmeelele ja Ühendkuningriigi ravimiamet tegi 28. septembril 2018 EMA-le vahekohtumenetluse alustamise esildise.
English: The European Commission issued an EU-wide legally binding decision on the marketing authorisation of Diotop on 31/01/2019.
Estonian: Euroopa Komisjon tegi Diotopi müügiloa kohta 31/01/2019 õiguslikult siduva otsuse, mis kehtib kogu Euroopa Liidus.
English: The Agency considered that, although the particular combination in Diotop (diclofenac 75 mg / omeprazole 20 mg) has never been tested in any published study, the data from studies of higher doses of diclofenac or other NSAIDs taken with omeprazole are enough to support the use of the specific combination in Diotop.
Estonian: EMA leidis, et kuigi Diotopis sisalduvat kombinatsiooni (diklofenak 75 mg / omeprasool 20 mg) ei ole üheski avaldatud uuringus kunagi käsitletud, on koos omeprasooliga võetud diklofenaki või muude NSAID-ravimite suuremate annuste uuringutest saadud andmed piisavad, et toetada Diotopis sisalduva erikombinatsiooni kasutamist.
English: The company submitted data from the published literature on the use of several NSAIDs (including diclofenac at the dose of 50 to 150 mg a day) and omeprazole in combination.
Estonian: Ettevõte esitas avaldatud kirjandusest pärinevad andmed mitme NSAID-ravimi (sh diklofenak annuses 50-150 mg ööpäevas) ja omeprasooli kombinatsiooni kasutamise kohta.
English: The Agency therefore concluded that the benefits of Diotop outweigh its risks, and therefore the marketing authorisation for Diotop should be granted in Germany.
Estonian: EMA järeldas seega, et Diotopi kasulikkus on suurem kui sellega kaasnevad riskid, ja seetõttu tuleb Saksamaal anda Diotopi müügiluba.
English: Diotop is used in adult patients who are at risk of developing stomach ulcers and whose disease is already controlled by diclofenac and omeprazole, the two active substances in Diotop, taken separately.
Estonian: Diotopi kasutatakse täiskasvanud patsientidel, kellel on maohaavandite tekke risk ja kelle haigust juba ravitakse Diotopi toimeainete diklofenaki ja omeprasooliga, mida võetakse eraldi.
English: EMA completes review following disagreement among EU Member States
Estonian: EMA vaatas pärast ELi liikmesriikide erimeelsust ravimiteabe läbi
English: Diotop is a medicine used to relieve symptoms such as swelling and pain caused by the joint disorders rheumatoid arthritis, osteoarthritis or ankylosing spondylitis.
Estonian: Diotop on ravim, millega leevendatakse liigesehaiguste reumatoidartriidi, osteoartriidi või anküloseeriva spondüliidi põhjustatud sümptomeid, näiteks turset ja valu.
English: Diclofenac is a nonsteroidal antiinflammatory drug (NSAID) used for the relief of pain and inflammation in a wide range of conditions.
Estonian: Diklofenak on mittesteroidne põletikuvastane aine (NSAID), millega leevendatakse valu ja põletikku paljude seisundite korral.
English: Omeprazole is a widely-used treatment for indigestion and acid reflux that acts by reducing the amount of acid the stomach makes.
Estonian: Omeprasool on laialdaselt kasutatav seedehäirete ja maosisu tagasiheite ravim, mille toimel väheneb maomahla eritumine.
English: This will help them to protect against the disease.
Estonian: See aitab kaitsta loomi haiguse eest.
English: Protection starts 25 days after the last injection and lasts for at least a year.
Estonian: Kaitse haiguse vastu tekib 25 päeva pärast viimast süsti ning püsib vähemalt 1 aasta.
English: This summary was last updated in April 2013.
Estonian: Kokkuvõtte viimane uuendus: 04-2013.
English: There may also be a local reaction at the injection site, such as swelling (generally lasting less than a week) or ‘nodules' (hardening under the skin) that may last for more than 6 or 7 weeks.
Estonian: Süstekohal võib tekkida paikne reaktsioon, näiteks turse, mis tavaliselt kestab vähem kui nädala, samuti väikesed sõlmed (nahaalune kõvenemine), mis võivad kesta üle 6-7 nädala.
English: The European Medicines Agency (EMA) reviewed additional information submitted according to an agreed timetable on the quality, safety and efficacy of the vaccine.
Estonian: Euroopa Ravimiamet vaatas läbi vastavalt kokkulepitud ajakavale esitatud vaktsiini kvaliteedi, ohutuse ja efektiivsuse lisateabe.
English: The European Commission granted a marketing authorisation valid throughout the EU for ZULVAC 8 Ovis on 15 January 2010.
Estonian: Euroopa Komisjon andis vaktsiini ZULVAC 8 Ovis müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 15. jaanuaril 2010.
English: The first injection is given from one and a half months of age and the second injection is given three weeks later.
Estonian: Esimene süst tehakse 1,5 kuu vanustele loomadele ja teine 3 nädalat hiljem.
English: The company also presented results from a series of studies with other vaccines that contain other serotypes of the bluetongue virus, as well as preliminary results from a study in sheep investigating how long the immunity produced by the vaccine lasted after vaccination.
Estonian: Ettevõte esitas ka mitme uuringu tulemused teiste vaktsiinide kohta, mis sisaldavad lammaste katarraalse palaviku viiruse teisi serotüüpe, samuti esialgsed tulemused lammastel tehtud uuringust, milles uuriti vaktsineerimisjärgse immuunsuse kestust.
English: The studies also showed that the vaccine can be used in pregnant sheep.
Estonian: Samuti näitasid uuringud, et vaktsiini tohib kasutada tiinetel lammastel.
English: Results from a series of laboratory safety trials performed with vaccines of similar composition but containing different serotypes of the virus were also presented.
Estonian: Esitati ka mitme laboratoorse ohutuskatse tulemused, mis viidi läbi sarnase koostise, kuid viiruse erinevat serotüüpi sisaldavate vaktsiinidega.
English: The withdrawal period is the time allowed after administration of the medicine before the animal can be slaughtered and the meat or milk used for human consumption.
Estonian: Keeluaeg on vaktsiini manustamisest arvestatav aeg, mille jooksul ei tohi looma tappa ega tema liha ega piima toiduks tarvitada.
English: Sheep may show a temporary increase in body temperature, no more than 1.2°C, in the 24 hours after vaccination.
Estonian: Lammastel võib 24 tunni jooksul pärast vaktsineerimist ajutiselt tõusta kehatemperatuur, tavaliselt kuni 1,2 °C võrra.
English: The vaccine also contains ‘adjuvants' (aluminium hydroxide and saponin) to enhance the immune response.
Estonian: Samuti sisaldab vaktsiin immuunvastuse tugevdamiseks adjuvante (toimet tugevdavaid aineid) alumiiniumhüdroksiidi ja saponiini.
English: In 2013 the CVMP considered that the submitted data were adequate for the authorisation of ZULVAC 8 Ovis to convert to a normal status.
Estonian: 2013. aastal leidis veterinaarravimite komitee, et esitatud andmed on piisavad, et muuta ZULVAC 8 Ovis müügiluba tavakorras väljastatuks.
English: In the future, if the animals are exposed to the bluetongue virus, the immune system will be able to produce antibodies more quickly.
Estonian: Kui loomad puutuvad hiljem lammaste katarraalse palaviku viirusega uuesti kokku, tekivad antikehad kiiremini.
English: The studies showed that the vaccine is safe for sheep and that it prevents viraemia in animals from one and a half months of age that are infected with bluetongue virus serotype 8.
Estonian: Uuringud näitasid, et vaktsiin on lammastele ohutu ning ennetab vireemiat vähemalt 1,5 kuu vanustel lammastel, kes on nakatunud lammaste katarraalse palaviku viiruse 8. serotüübiga.
English: The effectiveness of the vaccine in preventing viraemia in sheep was studied in a laboratory trial using the vaccine in sheep from one month of age.
Estonian: Vaktsiini efektiivsust vireemia ennetamisel lammastel uuriti laborikatses, mis hõlmas vaktsiini kasutamist vähemalt ühe kuu vanustel lammastel.
English: This means that it was not possible to obtain complete information about ZULVAC 8 Ovis at the time of the initial authorisation.
Estonian: See tähendab, et vaktsiini ZULVAC 8 Ovis kohta ei ole olnud esmase müügiloa andmisel võimalik saada täielikku teavet.
English: The vaccine is given to animals as an injection under the skin.
Estonian: Vaktsiini manustatakse loomadele nahaaluse süstina.
English: When it is given to sheep, the immune system recognises the viruses as ‘foreign' and makes antibodies against them.
Estonian: Kui lammastele manustatakse vaktsiini, peab immuunsüsteem viirust võõraks ja tekitab selle vastu antikehi.
English: The vaccine is used to prevent viraemia (the presence of the virus in the blood) in sheep from one and a half months of age.
Estonian: Vaktsiini kasutatakse vireemia (viiruse esinemine veres) ennetamiseks vähemalt 1,5 kuu vanustel lammastel.
English: The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of ZULVAC 8 Ovis exceed the risks in the prevention of viraemia caused by the bluetongue virus serotype 8 in sheep from one and a half months of age.
Estonian: Veterinaarravimite komitee järeldas, et vaktsiini ZULVAC 8 Ovis kasulikkus on suurem kui sellega kaasnevad riskid lammaste katarraalse palaviku viiruse 8. serotüübist põhjustatud vireemia ennetamisel vähemalt 1,5 kuu vanustel lammastel.
English: The benefit-risk balance may be found in the scientific discussion module of this EPAR.
Estonian: Vaktsiini kasulikkuse ja riski suhe on käesoleva Euroopa avaliku hindamisaruande teadusliku arutelu kokkuvõttes.
English: The withdrawal period for ZULVAC 8 Ovis for meat and milk is zero days.
Estonian: Vaktsiini ZULVAC 8 Ovis keeluaeg liha ja piima korral on 0 päeva.
English: ZULVAC 8 Ovis is a vaccine.
Estonian: ZULVAC 8 Ovis on vaktsiin.
English: ZULVAC 8 Ovis contains bluetongue viruses that have been inactivated so that they cannot cause the disease.
Estonian: ZULVAC 8 Ovis sisaldab lammaste katarraalse palaviku viirust, mis on inaktiveeritud (hävitatud) ega suuda seetõttu haigust tekitada.
English: ZULVAC 8 Ovis is a vaccine that contains inactivated (killed) bluetongue serotype 8 virus as the active substance.
Estonian: ZULVAC 8 Ovis on vaktsiin, mis sisaldab toimeainena lammaste katarraalse palaviku inaktiveeritud (hävitatud) viiruse 8. serotüüpi.
English: The safety of the vaccine was studied in laboratory safety studies carried out with ZULVAC 8 Ovis in sheep.
Estonian: Vaktsiini ZULVAC 8 Ovis ohutust uuriti lammaste laboratoorsetes ohutusuuringutes.
English: Inactivated vaccine against Bluetongue disease virus, serotype 8
Estonian: Lammaste katarraalse palaviku viiruse 8. serotüübi vaktsiin (inaktiveeritud)
English: It is available as a suspension for injection.
Estonian: Seda turustatakse süstesuspensioonina.
English: What is ZULVAC 8 Ovis?
Estonian: Mis on ZULVAC 8 Ovis?
English: ZULVAC 8 Ovis was initially authorised under ‘exceptional circumstances'.
Estonian: Vaktsiinile ZULVAC 8 Ovis anti müügiluba algselt erandkorras.
English: Why has ZULVAC 8 Ovis been approved?
Estonian: Miks vaktsiin ZULVAC 8 Ovis heaks kiideti?
English: How does ZULVAC 8 Ovis work?
Estonian: Kuidas ZULVAC 8 Ovis toimib?
English: What is the risk associated with ZULVAC 8 Ovis?
Estonian: Mis riskid vaktsiiniga ZULVAC 8 Ovis kaasnevad?
English: Other information about ZULVAC 8 Ovis:
Estonian: Muu teave vaktsiini ZULVAC 8 Ovis kohta
English: ZULVAC 8 Ovis is used in sheep to protect them against bluetongue disease, an infection caused by the bluetongue virus which is transmitted by midges.
Estonian: Vaktsiini ZULVAC 8 Ovis kasutatakse lammaste kaitsmiseks lammaste katarraalse palaviku eest.
English: How has ZULVAC 8 Ovis been studied?
Estonian: Kuidas vaktsiini ZULVAC 8 Ovis uuriti?
English: What is ZULVAC 8 Ovis used for?
Estonian: Milleks vaktsiini ZULVAC 8 Ovis kasutatakse?
English: What benefit has ZULVAC 8 Ovis shown during the studies?
Estonian: Milles seisneb uuringute põhjal vaktsiini ZULVAC 8 Ovis kasulikkus?
English: Information for patients and for healthcare professionals
Estonian: Patsientide ja tervishoiutöötajate teave
English: The specific recommendations of the CHMP are as follows:
Estonian: Inimravimite komitee konkreetsed soovitused on järgmised.
English: So far no alternative studies from other sources have been provided.
Estonian: Seni ei ole esitatud muudest allikatest pärinevaid uuringutulemusi.
English: • Patients should continue to take their medicines as prescribed.
Estonian: • Patsiendid peavad jätkama ravimite kasutamist määratud viisil.
English: Its suspension is therefore not expected to have any impact on patients in the EU.
Estonian: Seega ei mõjuta müügiloa peatamine eeldatavalt patsiente ELis.
English: Tel. +44 (0)20 3660 8427 E-mail: press@ema.europa.eu
Estonian: Tel +44 (0) 20 3660 8427 E-post: press@ema.europa.eu
English: The review of Alkem was initiated on 1 April 2016 at the request of the German medicines authority (BfArM), under Article 31 of Directive 2001/83/EC.
Estonian: Alkemi läbivaatamine algatati 1. aprillil 2016 Saksamaa ravimiameti (BfArM) taotlusel vastavalt direktiivi 2001/83/EÜ artiklile 31.
English: EMA recommends suspension of one medicine
Estonian: EMA soovitab peatada ühe ravimi müügiloa
English: The review covered medicines authorised via national procedures in individual EU Member States, whose marketing authorisation applications included data from studies conducted by Alkem Laboratories Ltd, Department of Bioequivalence, C-17/7, MIDC Industrial Estate, Taloja, Dist. Raigad410208 India.
Estonian: Läbivaatamismenetlus hõlmas üksikutes ELi liikmesriikides riiklike menetlustega heaks kiidetud ravimeid, mille müügilubade taotlused sisaldasid andmeid uuringutest, mille läbiviija oli Alkem Laboratories Ltd., Department of Bioequivalence, C-17/7, MIDC Industrial Estate, Taloja, Dist. Raigad410208 India.
English: EMA will continue to work closely with national authorities and international partners to ensure that studies underpinning marketing authorisations in the EU are carried out to the highest standards and that companies continue to comply fully with all aspects of Good Clinical Practice (GCP).
Estonian: EMA teeb tihedat koostööd liikmesriikide ametiasutuste ja rahvusvaheliste partneritega, et tagada, et Euroopa Liidus müügilubade aluseks olevad uuringud tehtaks kooskõlas rangeimate standarditega ning asjaomased ettevõtted järgiksid täies ulatuses heade kliiniliste tavade kõiki aspekte.
English: The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States on 8 September 2016.
Estonian: Inimravimite komitee arvamus edastati Euroopa Komisjonile, kes tegi 8. septembril 2016 õiguslikult siduva lõpliku otsuse, mida kohaldatakse kõigis Euroopa Liidu liikmesriikides.
English: The findings cast doubts on the quality management system in place at the site, and thus on the reliability of the data of bioequivalence studies conducted between March 2013 and March 2015.
Estonian: Tuvastatud faktid tõstatavad kahtlusi üksuse kvaliteedijuhtimissüsteemi suhtes ning seega ka 2013. aasta märtsist kuni 2015. aasta märtsini tehtud bioekvivalentsusuuringute andmete usaldusväärsuses.
English: The review was carried out by the Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which has adopted the Agency's opinion.
Estonian: Läbivaatamise teostas inimravimite komitee, kes vastutab inimravimitega seotud küsimuste eest ja kes võttis vastu Euroopa Ravimiameti arvamuse.
English: The recommendations followed a joint routine inspection by German and Dutch authorities in March 2015, which revealed misrepresentation of data during the conduct of two different trials performed in 2013 and 2014 at the Taloja site.
Estonian: Soovituste aluseks on 2015. aasta märtsis toimunud Saksamaa ja Madalmaade ametiasutuste rutiinse ühiskontrolli tulemused, milles tuvastati andmete ebaõige esitamine kahe erineva uuringu läbiviimisel Talojas asuvas üksuses 2013. ja 2014. aastal.
English: 8 September 2016 EMA/633777/2016 Rev. 1
Estonian: 8. september 2016 EMA/632642/2016
English: The CHMP's recommendations concerning these medicines were sent to the European Commission, which issued a legally binding decision valid throughout the EU.
Estonian: Inimravimite komitee arvamus nende ravimite kohta edastati Euroopa Komisjonile ja komisjon tegi kogu Euroopa Liidus seaduslikult siduva otsuse.
English: More about the medicines
Estonian: Ravimite lisateave
English: Other riluzole-containing medicines remain available.
Estonian: Teised rilusooli sisaldavad ravimid jäävad turule.
English: • Cefuroxime Alkem and Cefuroxime Krka (antibiotics) can remain on the market in the EU, as alternative studies have been provided that support a positive benefit-risk balance.
Estonian: • Cefuroxime Alkem ja Cefuroxime Krka (antibiootikumid) võivad jääda ELi turule, sest esitatud on teistest allikatest pärinevaid uuringuid, mis toetavad kasulikkuse ja riski positiivset suhet.
English: On 23 June 2016, the European Medicines Agency (EMA) recommended the suspension of a medicine (Riluzole Alkem), for which studies were conducted at the Alkem Laboratories Ltd site in Taloja, India, and has required companies to provide new data for another medicine before it can be authorised in the EU.
Estonian: 23. juunil 2016 soovitas Euroopa Ravimiamet (EMA) peatada ravimi Riluzole Alkem müügiloa, mille uuringud olid tehtud ettevõtte Alkem Laboratories Ltd. Indias Talojas asuvas üksuses, ja palus ettevõtetel enne ELis müügiloa andmist esitada teise ravimi kohta uusi andmeid.
English: As a result, a medicine is being suspended.
Estonian: Seetõttu on ravimi müügiluba peatatud.
English: EMA's Committee for Medicinal Products for Human Use (CHMP) noted that, although there is no evidence of harm or lack of effectiveness linked to the conduct of studies by Alkem Laboratories Ltd, the studies cannot be accepted in marketing authorisation applications in the EU.
Estonian: EMA inimravimite komitee märkis, et kuigi puuduvad tõendid ettevõtte Alkem Laboratories Ltd. tehtud uuringutega seotud kahjulikkuse või ebaefektiivsuse kohta, ei saa neid uuringuid ELis müügilubade taotluste läbivaatamisel aktsepteerida.
English: It also included ongoing marketing authorisation applications for medicines which use study data from the site.
Estonian: Menetlus hõlmas ka ravimite müügilubade taotluste pooleliolevaid hindamisi, milles kasutati nimetatud üksuses tehtud uuringute andmeid.
English: • The medicine being suspended, Riluzole Alkem, contains riluzole and is not yet on the market in the EU.
Estonian: • Ravim Riluzole Alkem, mille müügiluba peatatakse, sisaldab rilusooli ja ELis seda veel ei turustata.
English: • Ibuprofen Orion, a painkiller currently under evaluation by national authorities, cannot be authorised on the basis of studies carried out at Alkem Laboratories Ltd.
Estonian: • Valuvaigisti Ibuprofen Orion (mida praegu hindavad riiklikud ametiasutused) müügiluba ei saa anda ettevõttes Alkem Laboratories Ltd. tehtud uuringute põhjal.
English: • Cefuroxime Ingen Pharma, currently under evaluation by national authorities, can still be considered for authorisation, as studies from other sources have been provided.
Estonian: • Ravimi Cefuroxime Ingen Pharma (mida praegu hindavad riiklikud ametiasutused) müügiloa andmist saab kaaluda, sest esitatud on teistest allikatest pärinevaid uuringutulemusi.
English: Therefore, the Committee recommended that medicines authorised or being evaluated on the basis of these studies should be suspended or refused authorisation, unless alternative data are available from other sources.
Estonian: Seetõttu soovitas komitee peatada nende uuringute põhjal antud ravimite müügiload ning keelduda nende uuringute alusel hinnatavate ravimite müügilubade andmisest, kui puuduvad muudest allikatest saadud andmed.
English: • Some studies carried out at the Alkem Laboratories Ltd site have been found to be flawed.
Estonian: • Mõnes Alkem Laboratories Ltd. üksuses tehtud uuringus on tuvastatud vigu.
English: Medicines under evaluation cannot be granted authorisation on the basis of these studies; further data would have to be provided to support authorisation.
Estonian: Hindamisel olevatele ravimitele ei saa nende uuringute alusel müügiluba anda.
English: • Riluzole Alkem, a medicine for amyotrophic lateral sclerosis (ALS) which has yet to be marketed in the EU, should now be suspended.
Estonian: • Amüotroofse lateraalskleroosi (ALS) ravimi Riluzole Alkem müügiluba tuleb peatada; ravim ei ole veel ELi turule jõudnud.
English: • There is no evidence of harm or lack of effectiveness with any of the medicines linked to studies conducted by Alkem Laboratories Ltd.
Estonian: • Ettevõttes Alkem Laboratories Ltd. tehtud uuringutega seostatavate ravimite puhul ei ole tuvastatud kahjulikkust ega ebaefektiivsust.
English: The European Commission issued a decision on 28 September 2017.
Estonian: Euroopa Komisjon tegi otsuse 28. septembril 2017.
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28 September 2017
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom28.
English: Outcome of a referral procedure under Article 35 of Directive 2001/82/EC (EMEA/V/A/124)
Estonian: Direktiivi 2001/82/EÜ artikli 35 kohase esildismenetluse (EMEA/V/A/124) tulemused
English: Consequently, on 1 September 2016, France initiated a procedure under Article 35 of Directive 2001/82/EC for the aforementioned veterinary medicinal products.
Estonian: Seetõttu algatas Saksamaa 1. septembril 2016 direktiivi 2001/82/EÜ artikli 35 kohase menetluse, milles käsitletakse eespool nimetatud veterinaarravimeid.
English: Which data has the CVMP reviewed?
Estonian: Mis andmed veterinaarravimite komitee läbi vaatas?
English: The CVMP recommended that variations to the terms of the marketing authorisations for the aforementioned veterinary medicinal products are required in order to amend the product information accordingly.
Estonian: Veterinaarravimite komitee soovitas muuta eespool nimetatud veterinaarravimite müügilubade tingimusi, et muuta nende ravimiteavet.
English: The veterinary medicinal products Zanil and associated names, and generic products thereof, are oral suspensions containing 34 mg oxyclozanide per ml.
Estonian: Veterinaarravim Zanil ja sarnased nimetused ning nende geneerilised ravimid on suukaudsed suspensioonid, mis sisaldavad 34 mg/ml oksüklosaniidi.
English: France noted that across the European Union for Zanil and associated names, and generic products thereof, there are different approved withdrawal periods for cattle, sheep and goats, e.g. cattle meat and offal from 10 days to 28 days; cattle milk from zero hours to 108 hours; sheep meat and offal from 14 days to 28 days; sheep milk from ‘do not use in sheep producing milk for human consumption' to 7 days; goat meat and offal 14 days; goat milk zero days.
Estonian: Prantsusmaa juhtis tähelepanu, et Zanili ja sarnaste nimetuste ning nende geneeriliste ravimite puhul on Euroopa Liidus kehtestatud erinevad veiste, lammaste ja kitsede keeluajad, näiteks veiste liha ja söödavate kudede korral varieerusid keeluajad 10 päevast 28 päevani; lehmapiima keeluajad nullist tunnist 108 tunnini; lammaste liha ja söödavate kudede keeluajad 14 päevast 28 päevani; lammaste piima keeluajad märkest „Mitte kasutada lammaste raviks, kelle piima tarvitatakse inimtoiduks“ 7 päevani; kitsede liha ja söödavate kudede keeluaeg oli 14 päeva ja kitsede piima keeluaeg null päeva.
English: Questions and answers on Zanil and associated names, and generic products thereof EMA/586006/2017
Estonian: Zanili ja sarnaste nimetuste ning nende geneeriliste ravimite teave EMA/707681/2017